



University of Connecticut
OpenCommons@UConn

SoM Articles

School of Medicine

2007

Role of Ashwagandha (*Withania Somnifera*) in Immune Modulation: Proposed Influence in Immune-Regulation

Subhasis Chattopadhyay

University of Connecticut School of Medicine and Dentistry

Robert E. Cone

University of Connecticut School of Medicine and Dentistry

Follow this and additional works at: https://opencommons.uconn.edu/som_articles

 Part of the [Alternative and Complementary Medicine Commons](#)

Recommended Citation

Chattopadhyay, Subhasis and Cone, Robert E., "Role of Ashwagandha (*Withania Somnifera*) in Immune Modulation: Proposed Influence in Immune-Regulation" (2007). *SoM Articles*. 20.

https://opencommons.uconn.edu/som_articles/20

Role of Ashwagandha (*Withania somnifera*) in immune modulation: Proposed influence in Immune-regulation

Subhasis Chattopadhyay and Robert E. Cone
Department of Immunology, Connecticut Lions Vascular Eye Center,
University of Connecticut Health Center,
Farmington, CT 06030, USA

Abstract: The immune system evolved to protect organisms from an infinite variety of disease-causing agents but to avoid harmful responses to self. However, such a powerful defense mechanism requires regulation. Immune regulation includes homeostatic and cell-mediated targeted mechanisms to the activation, differentiation and function of antigen-triggered immuno-competent cells and immuno-regulatory cells. The regulation of the immune system has been a major challenge for the management of autoimmune disorders, tumor immunity, infectious diseases and organ transplants. However, immuno-modulatory procedures used by modern medicine to induce immunoregulatory function have deleterious side effects. Ashwagandha (*Withania somnifera*), an herb used in Ayurvedic medicine is being tested and used in experimental and clinical cases with potential immuno-modulatory functions without any side effects. Here we propose future usages of Ashwagandha for immuno-regulatory function in translational research.

Ashwagandha: an immunoregulatory herb

Immune protective mechanisms include the elaboration of potent inflammatory molecules, antibodies, and killer cell activation — which together not only destroy invading microorganisms, pathogenic autoreactive cells, and tumors, but also may mortally injure normal cells. Accordingly, the immune response is tightly regulated by immuno-regulatory cells, cytokines and external influences.

Withania somnifera Dunal (Ashwagandha), also known as Indian ginseng, belongs to the family Solanaceae, which is distributed throughout India. It is widely used in the Ayurvedic system of medicine to treat tumors, inflammation, arthritis, asthma, and hypertension (1). Ashwagandha has been used as an immunostimulant and as a dietary supplement (1, 2). Although it has been reported to selectively enhance T helper 1 (Th1) immune responses (2, 3), Ashwagandha also has anti-inflammatory function (4).

Understanding the immuno-modulatory mechanisms of Ashwagandha can provide insight into immune function and regulation that could further help in immunoregulatory procedures. Chemical investigation with the extract of roots and leaves of *Withania somnifera* (WS) have yielded bioactive withanolides, which inhibit cyclooxygenase enzymes, lipid peroxidation, and the proliferation of tumor cells (reviewed in 5). It has been reported that WS extract preferentially reduces inflammatory processes by inactivating nuclear factor-kappaB (NF-kB) activation, by inducing cellular death by apoptosis, inhibiting inflammation and abolishing osteoclastogenesis through suppression of NF-kB activation and NF-kB-regulated gene expression (5). Similar studies show that the leaf extract of WS, as well as its major constituent withaferin A (WA), potently inhibits NF-kB activation by preventing the tumor necrosis factor-induced activation of I-kappaB kinase beta (6). This study indicates that pure WA or WA-enriched WS extracts can be considered as a novel class of NF-kB inhibitors, which hold promise as novel anti-inflammatory agents for the treatment of various inflammatory disorders and/or cancer. It has been proposed that the antiproliferative, proapoptotic, anti-invasive, antiosteoclastogenic, antiangiogenic, antimetastatic, radiosensitizing, antiarthritic, and cardioprotective effects assigned to withanolide may be mediated in part through the suppression of NF-kB and NF-kB-regulated gene products (5).

Recently, withaferin A (made from the crushed air-dried leaves of *Withania somnifera* Dun.) was used to induce apoptosis in parasitic protozoa *Leishmania donovani*, which acts as a novel protein kinase inhibitor and it is facilitated by apoptotic topoisomerase I-DNA complex (7). The anti-microbial effect of WS was also shown in a prophylactic administration of WS extract, which increases host resistance in *Listeria monocytogenes*-infected mice (8). Moreover, the therapeutic role of *Withania* has potential usage in inflammation and the patho-physiology of immune regulation. In summary the potential roles of Ashwagandha in immune modulation is shown in Fig. 1 along with its curative usage for different diseases.

Ashwagandha: the future candidate for experimental and clinical immunology research

The future lines of basic and translational research with *Withania* must enroll the investigation for immunoregulatory cells, which are the cellular feedback regulators of an immune response.

The involvement of such immuno-regulatory cells induced by WS might have several functions: such as regulating antigen presentation and an immunosuppressive microenvironment along with a physiological cytokine milieu for an effector T cell function. It is intriguing that the treatment of *Withania* induces a Th1 cell-mediated immune response and an elevation of IgG2a-mediated humoral immune responses (2, 3). In addition, the aqueous suspension of WS shows anti-inflammatory and immunosuppressive effects by inhibiting the complement system, mitogen-induced lymphocyte proliferation and delayed type hypersensitivity (DTH) in rats (4). Although in this investigation no effect on the humoral response was observed, others have reported elevated levels of IgG2a over IgG1 in the WS-treated BALB/c mice (3). There may be differential effect(s) and/or alternative responsiveness of WS treatment between mouse strains and rats for immune activation versus suppression. Accordingly, a comparative study of different forms of WS extract is warranted towards the understanding of respective immune modulation in different contexts. The induction of regulatory T cells (Treg) and the immune suppression of effector T cell functions have been reported by others and us in tumor immunity (9-12) and ocular immune privilege (13, 14). However, the effect of *Withania* on the immuno-regulatory cellular response has not been tested yet. Accordingly, this natural product is a future candidate that might address the cross-talk between the effector immune cell response and the influence of a Treg response.

Finally, investigations into the use of preparation of *Withania somnifera*, in concert with the holistic Ayurvedic approaches to treat immunoregulatory disorders may impact on several forms of autoimmune diseases, tumor progression, parasitic infection, inflammation, organ transplantation and stress.

Corresponding Author:

Robert E. Cone, Ph.D.
Department of Immunology,
University of Connecticut Health Center,
263 Farmington Avenue, Farmington, CT 06030-3105, USA.
Telephone: 860-679-3611; Fax: 860-679-2936
Email: cone@uchc.edu

References:

1. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of *Withania somnifera* (ashwagandha): a review. *Altern Med Rev*. 2000. 5:334-346
2. Malik F, Singh J, Khajuria A, Suri KA, Satti NK, Singh S, Kaul MK, Kumar A, Bhatia A, Qazi GN. A standardized root extract of *Withania somnifera* and its major constituent withanolide-A elicit humoral and cell-mediated immune responses by up regulation of Th1-dominant polarization in BALB/c mice. *Life Sci*. 2007. 80:1525-1538
3. Bani S, Gautam M, Sheikh FA, Khan B, Satti NK, Suri KA, Qazi GN, Patwardhan B. J Ethnopharmacol. Selective Th1 up-regulating activity of *Withania somnifera* aqueous extract in an experimental system using flow cytometry. 2006. 107:107-115.
4. Rasool M, Varalakshmi P. *Vascul Pharmacol*. Immunomodulatory role of *Withania somnifera* root powder on experimental I induced inflammation: An in vivo and in vitro study. 2006. 44:406-4105.
5. Ichikawa H, Takada Y, Shishodia S, Jayaprakasam B, Nair MG, Aggarwal BB. Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression. *Mol Cancer Ther*. 2006. 5:1434-1445.
6. Kaileh M, Vanden Berghe W, Heyerick A, Horion J, Piette J, Libert C, De Keukeleire D, Essawi T, Haegeman G. Withaferin A strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. *J Biol Chem*. 2007. 282:4253-4264.
7. Sen N, Banerjee B, Das BB, Ganguly A, Sen T, Pramanik S, Mukhopadhyay S, Majumder HK. Apoptosis is induced in leishmanial cells by a novel protein kinase inhibitor withaferin A and is facilitated by apoptotic topoisomerase I-DNA complex. *Cell Death Differ*. 2007. 14:358-367.8.
8. Teixeira ST, Valadares MC, Goncalves SA, de Melo A, Queiroz ML. Prophylactic administration of *Withania somnifera* extract in creases host resistance in *Listeria monocytogenes* infected mice. *Int Immunopharmacol*. 2006. 6:1535-1542.
9. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. *Nat Immunol*. 2002. 3:999-1005.
10. Chattopadhyay S, Chakraborty NG, Mukherji B. Regulatory T cells and tumor immunity. *Cancer Immunol Immunother*. 2005. 54:1153-1161.
11. Chattopadhyay S, Chakraborty NG. Continuous presence of Th1 conditions is necessary for longer lasting tumor-specific CTL activity in stimulation cultures with PBL. *Hum Immunol*. 2005. 66:884-891.
12. Chattopadhyay S, Mehrotra S, Chhabra A, Hegde U, Mukherji B, Chakraborty NG. Effect of CD4+CD25+ and CD4+CD25- T regulatory cells on the generation of cytolytic T cell response to a self but human tumor-associated epitope in vitro. *J Immunol*. 2006. 176:984-990
13. Niederkorn JY. Regulatory T cells and the eye. *Chem Immunol Allergy*. 2007. 92:131-9.
14. Cone RE, Chattopadhyay S and O'Rourke J. Immunoregulatory Pathways Connecting The Eye, The Immune system and The Sympathetic Nervous System. 2007. *Current Trends in Immunology*. In Press.




Fig. 1. Effect of Ashwagandha (*Withania somnifera*) in the cellular and biochemical function(s) as an immune-modulator and its usage for the treatment of different diseases